**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 64985

**Manuscript Type:** MINIREVIEWS

**Small duct primary sclerosing cholangitis: a discrete variant or a bridge to large duct disease, a practical review**

Nguyen CM *et al*. Small duct primary sclerosing cholangitis

Christopher M Nguyen, Kevin T Kline, Heather L Stevenson, Kashif Khan, Sreeram Parupudi

**Christopher M Nguyen,** department ofInternal Medicine, The University of Texas Medical Branch, Galveston, TX 77555, United States

**Kevin T Kline, Kashif Khan, Sreeram Parupudi,** department of Gastroenterology and Hepatology, The University of Texas Medical Branch, Galveston, TX 77555, United States

**Heather L Stevenson,** department of Pathology, University of Texas Medical Branch, Galveston, Tx 77555, United States

**Author contributions:** Nguyen CM and Kline KT contributed to thedraft and conception; Kline KT and Stevenson HL revised the manuscript; Stevenson HL provided original pathology images; Khan K and Parupudi S contributed to conception, revision and final approval.

**Corresponding author: Christopher M Nguyen, DO, Doctor,** department of Internal Medicine, The University of Texas Medical Branch, 301 University Boulevard, John Sealy Annex Room 4.108, Galveston, TX 77555, United States. chmnguye@utmb.edu

**Received:** February 26, 2021

**Revised:** May 12, 2021

**Accepted: February 15, 2022**

**Published online:**

**Abstract**

The natural history, associations with inflammatory bowel disease (IBD), and long-term outcomes of large duct primary sclerosing cholangitis (ldPSC) have been well documented. Small duct primary sclerosing cholangitis (sdPSC) is a much less common and relatively more benign variant. The natural history of sdPSC has been difficult to characterize given the limited number of studies in the literature especially with regards to the subset of patients who progress to large duct involvement. It has been unclear whether sdPSC represented a subset of ldPSC, an earlier staging of ldPSC, or a completely separate and distinct entity of its own. Strong associations between sdPSC and IBD have been established with suspicion that concurrent sdPSC-IBD may be a key prognostic factor in determining which patients are at risk of progression to ldPSC. Little is known regarding the discrete circumstances that predisposes some patients with sdPSC to progress to ldPSC. It has been suspected that progression to large biliary duct involvement subjects this subset of patients to potentially developing life-threatening complications. Here the authors conducted a thorough review of the published sdPSC literature using Pubmed searches and cross-referencing to compile all accessible studies regarding cohorts of sdPSC patients in order better characterize the subset of sdPSC patients who progress to ldPSC and the associated outcomes.

**Key Words:** Small duct primary sclerosing cholangitis; Inflammatory bowel disease; Progression; Primary sclerosing cholangitis; Outcomes

Nguyen CM, Kline KT, Stevenson HL, Khan K, Parupudi S. Small duct primary sclerosing cholangitis: a discrete variant or a bridge to large duct disease, a practical review. *World J Hepatol* 2022; In press

**Core Tip:** Strong associations between small duct primary sclerosing cholangitis (sdPSC) and inflammatory bowel disease (IBD) have been established with suspicion that concurrent sdPSC-IBD may be a key prognostic factor in determining which patients are at risk of progression to ldPSC.

**INTRODUCTION**

Primary sclerosing cholangitis (PSC) is a chronic liver disease with the potential of progression to cirrhosis that is characterized by multi-focal cholestatic inflammation and fibrosis[1-3]. PSC has an incidence of 0.9 to 1.3 cases per 100,000 in the United States[2,4]. PSC has a close association with inflammatory bowel disease (IBD) and has a risk of developing various hepatobiliary malignancies including cholangiocarcinoma (CCA)[1-3]. Classic or large-duct primary sclerosing cholangitis (ldPSC) has very distinct clinical, cholangiographic, and histologic features with cholangiography typically establishing a diagnosis[1,3-5]. In 1985, Ludwig *et al* brought into question the possibility of small intra-hepatic biliary duct involvement which led to pathologic studies in 1991 confirming the diagnosis of small duct primary sclerosing cholangitis (sdPSC), also referred to as pericholangitis[6].

The natural history, associations with IBD, and long-term outcomes of ldPSC have been well documented. Small duct primary sclerosing cholangitis is a much less common and relatively more benign variant[7-9]. In recent years, it has been discovered that this variant can rarely progress to having large biliary duct involvement[7-14]. Several studies have attempted to characterize this unique subset of patients, with the rate of progression to ldPSC ranging from 7.1-22.9%[7-9,11-14]. Little is known regarding the etiology or discrete circumstances that predisposes some patients with sdPSC to progress to ldPSC. It is known, however, that progression to large biliary duct involvement subjects this subset of patients to potentially developing life-threatening complications[8,9].

The natural history of sdPSC has been difficult to characterize given the limited number of studies in the literature. Describing the subset of patients who have progressed to ldPSC is even more challenging. The authors conducted a thorough evaluation of the published literature to compile all accessible studies regarding cohorts of sdPSC patients using Pubmed searches and cross-referencing. Table 1 summarizes the individual studies, the baseline characteristics, and outcomes of each cohort of sdPSC patients.

**Genetic Pathogenesis**

The etiology of PSC is not well understood however it is believed to be predominantly autoimmune due to its association with elevated levels of antineutrophilic cytoplasmic, antinuclear, and anticardiolipin antibodies in addition to the HLA DR3 and HLA B8 genes[2,4,15]. A strong association between PSC and IBD has also been well established with studies showing a significantly increased risk of developing PSC and UC in first-degree relatives of patients who have PSC with or without UC[3,4,16,17].

The etiology of sdPSC is even less understood, though it carries a more favorable prognosis than its large-duct counterpart[8]. It has been unclear whether sdPSC represented a subset of ldPSC, an earlier staging of ldPSC, or a completely separate and distinct entity of its own[8,10]. A study evaluating the components of sdPSC within the subset of patients with and without concomitant IBD suggested the strongest association existed between HLD-DRB1\*13:01 and sdPSC[15]. In contrast to the strong association of HLA-B\*08 with ldPSC, HLA-B\*08 was found to be more prevalent in sdPSC when compared to healthy controls, but not to the extent found in ldPSC[15]. Additionally, patients that have the DRB1\*13:01 haplotype are at an increased risk of developing IBD[15]. A noteworthy hypothesis drawn from this study is the notion that patients with sdPSC and concomitant IBD could represent precursors to classic PSC while those sdPSC patients without IBD may actually represent a different biliary disease process, such as primary biliary cholangitis, or a secondary cause of sclerosing cholangitis, such as those related to the ABCB4 gene[15].

**Environmental Pathogenesis**

It has been speculated that in addition to genetic factors, environmental factors contribute to the pathogenesis of PSC in part due to persistent insult to the cholangiocytes[2-4]. More recent studies suggest the involvement of the gastrointestinal microbiome and its metabolites as an important and modifiable component of the pathogenesis of PSC[3,4]. The relationship of PSC with the enteric microbiome, known as the “leaky gut” hypothesis, describes the passive translocation of bacterial products from an inflamed gut to the portal venous system triggering an inflammatory cascade that leads to the characteristic “onion skinning” intrahepatic biliary duct fibrosis that is seen in all variants of PSC[2,4,18,19]. The development of the laminar concentric fibrosis interrupts the arterial and biliary interface causing ischemia to the cells lining the biliary system[4]. Injured cholangiocytes facilitate the pathogenic strictures and fibrosis through the secretion of inflammatory cytokines and chemokines[2,4]. Other theories exist focused on defects in the protective mechanisms against toxicity from bile acids, gut-derived T cell recruitment to the liver, and even disruptions in bile homeostasis as potential key factors in PSC pathogenesis[2,4].

Based on initial investigation of the pathophysiologic association of hepatobiliary disorders and colonic inflammation, the role of bacterial chemotactic peptides in the development of sdPSC has been evaluated[20,21]. Colitis was induced in the specimens using intrarectal infusions of acetic acid and saline, followed by intrarectal infusion of N-formyl L-methionine L-leucine L-tyrosine (fMLT), a bacterial chemotactic peptide produced by *Escherichia coli*. The experimentally induced colitis and rectal fMLT induction resulted in an eight-fold increase in biliary excretion of fMLT. Liver specimens showed evidence of pericholangitis affecting the small biliary ducts suggesting bacterial chemotactic peptides could play a pathogenic role in the development of sdPSC[20].

**Epidemiology and Natural History**

Approximately 75% of patients with PSC have both small and large duct involvement, while 15% have only small duct and 10% with only large duct involvement[3,8]. PSC often insidiously progresses to advanced liver disease with an estimated 10-year survival of 65%[2,3]. LdPSC affects men twice as frequently as women and typically presents within the fourth decade of life with the mean age of diagnosis being 41 years[3]. However, a study in Norway suggested that PSC may occur as commonly in females as in males but with a more clinically subtle course[5]. The incidence per year is estimated to be 0.9-1.3 per 100,000 and the prevalence is approximately 0.5-16.2 per 100,000 patients in the United States[4,5]. Studies in Asia and Spain have reported a lower prevalence of up to 10-fold when compared to the US and EU[22-24]. Some studies suggest an increase in the incidence of PSC in recent decades though this trend has also been associated with other autoimmune and idiopathic inflammatory disorders and could be related to increased use of magnetic resonance cholangiography[3]. Approximately 70% of patients with PSC have concurrent IBD with UC accounting for 80% of PSC-IBD patients, while CD and intermediate colitis affects 10% each[2,3,5]. Hepatobiliary malignancies affect up to 10.9% of PSC patients with a five-fold increased risk of colorectal cancer when compared to IBD patients without PSC[3,25].

SdPSC is more benign when compared to ldPSC with most mortality limited to the small subset that progress to large-duct involvement or who develop liver failure[8]. Studies have shown a median survival of 29.5 years in sdPSC *vs* only 17 years in ldPSC without liver transplantation[8,10,23,26]. SdPSC seems to have a similar predilection for male gender however percentages vary across individual studies. Evaluating the data in Table 1 yielded a 60.9% male predominance of sdPSC across all studies of adult and pediatric populations. The annual incidence of sdPSC is estimated to be 0.15 per 100,000 patients and the median age of diagnosis is 35 and 9.5 years in adults and children respectively[8,10,27]. IBD affects approximately 80% of sdPSC patients with the large majority being diagnosed at initial presentation[8,27]. Of the patients with sdPSC and concomitant IBD, approximately 78% have UC, 21% CD, and 1% an intermediate colitis[8,15]. A study describing differences between sdPSC patients with and without IBD reported a mortality of 9% and 7% respectively and transplantation in 6% and 14% respectively[15]. Hepatobiliary malignancies are extremely rare in sdPSC with very few reported cases. One long-term retrospective, multi-institutional study reported approximately one-fourth of patients with sdPSC may show evidence of progression to ldPSC[8].

**CLINICAL PRESENTATION**

PSC has a highly variable initial presentation with approximately 50% of patients being asymptomatic at presentation and up to 40% of cases being incidentally diagnosed after routine blood work revealing cholestatic elevation of liver enzymes[3,4]. Those who go without early incidental detection can present with the sequelae of advanced liver disease[4]. Patients who develop symptoms at the time of diagnosis typically present with weight loss, jaundice, pruritis, abdominal pain, diarrhea, fever, and fatigue[1]. Patients with sdPSC present with generally similar symptoms though weight loss and jaundice at diagnosis is more significantly seen in ldPSC than in sdPSC[8,10].

**DIAGNOSIS**

Several factors contribute to the clinical diagnosis of PSC. The first includes a cholestatic elevation in liver biochemical testing, specifically with a significantly higher elevation in serum alkaline phosphatase compared to milder elevations in the serum aminotransferases[1]. Concomitant autoimmune hepatitis may cause more substantial elevations in the serum aminotransferases[1,28]. Second, cholangiographic findings of multifocal intrahepatic, extrahepatic, or a combination of both are typically seen[1]. Lastly, a liver biopsy may be warranted in the appropriate context to exclude other diseases, establish stage of disease, or to diagnose sdPSC[1]. Not all patients will present with a significant elevation in serum alkaline phosphatase so a strong clinical suspicion should warrant further investigation with magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous transhepatic cholangiography (PTC)[1,5]. Cholangiography is negative in sdPSC due to the involvement of biliary ducts that are less than 100 micro millimeters making liver biopsy necessary to confirm the diagnosis of sdPSC[10]. The subset of sdPSC patients who progress to large-duct involvement will develop the characteristic cholangiographic findings in classic PSC[10,14].

**Histopathologic features of sdPSC**

Most studies have reported that sdPSC has similar histopathologic features as PSC, albeit with normal imaging findings[10]. As mentioned above, several studies have reported that sdPSC may just be an earlier form of well-developed PSC[8].Therefore, the histopathologic features may be subtle and easily missed[10].At our institution, we recently encountered a 35-year-old female that reported intermittent pruritis with previous episodes of jaundice and persistently elevated alkaline phosphatase.  An MRCP showed no abnormalities within the biliary tract, sdPSC was suspected, and a liver biopsy was performed.  The liver biopsy was evaluated by a board-certified hepatopathologist and showed several portal tracts containing atrophic bile ducts (i.e., evidence of biliary senescence changes).  These were subtle by hematoxylin and eosin (H&E) evaluation (Figure 1A); however, additional stains were able to highlight peribiliary sclerosis with focal areas of fibrous bile duct obliteration (Figure 1B). Cytokeratin 7 (Figure 1C) and copper stains (Figure 1D) were helpful to confirm the presence of chronic biliary injury and suboptimal bile flow[29].

**Associated disorders**

Similar to ldPSC, sdPSC has a strong association with IBD. The large majority of sdPSC patients present with concurrent UC[8,15]. A key difference from ldPSC is a higher prevalence of Crohn’s disease with a study showing a prevalence of 21% in sdPSC *vs* 5-10% in ldPSC populations[8]. Studies have not shown any significant differences in outcomes when comparing sdPSC-UC and sdPSC-CD populations[8,10,15,30]. Hepatobiliary cancers in sdPSC are quite rare with only 1 documented case of hepatocellular carcinoma in all of the evaluated studies[11]. In contrast, cholangiocarcinoma (CCA) is seen in approximately 15% of ldPSC patients while cases seen in sdPSC are exceedingly rare[31]. Additionally, ldPSC patients have five times increased risk of developing colorectal cancer when presenting with concurrent IBD when compared to ldPSC patients without IBD[4,25]. This association with malignancies is the thought behind routine colorectal screening in those with PSC-IBD and may warrant evaluation for the need of routine surveillance in the sdPSC-IBD population. An overlap syndrome exists between PSC and autoimmune hepatitis (AIH) which is more commonly seen in the pediatric population though adult PSC patients can develop superimposed AIH years after the initial PSC diagnosis[27,28]. A similar trend is seen in sdPSC as the majority of sdPSC-AIH patients were seen in the pediatric populations[27,28,32]. Other disorders associated with PSC include type I diabetes mellitus, membranoproliferative glomerulonephritis, hypothyroidism, and autoimmune hemolytic anemia though the prevalence of these conditions in sdPSC have not been as well established[8,10].

**Treatment**

No widely accepted method of therapy has been established for patients with ldPSC or sdPSC in part, due to ambiguity regarding the pathogenesis of the disease. Ursodeoxycholic acid (UDCA) at lower doses improved serum liver biochemical tests however there was little symptomatic improvement and no significant improvement in overall outcomes[33,34]. A study using moderate doses of UDCA failed to produce a statistically significant outcome[35]. Most recently a multi-center study examining high doses of UDCA was aborted due to increased morbidity and mortality despite improvement in serum biochemical profiles[1]. The major gastroenterology societies within the United States recommend against the use of UDCA in patients with PSC[1]. Additionally, the role of immunosuppressive agents and corticosteroids in the treatment of PSC has been explored[1,36,37]. However, no studies demonstrated significant improvement in morbidity and mortality with these agents.

Ultimately, the only definitive therapy for PSC is liver transplantation which has a five-year survival rate of nearly 85%[1,38]. A possibility of recurrence has been seen in 20-25% of cases, 5-10 years post-transplant[38]. Patients with sdPSC have a significantly longer median survival without liver transplantation compared to those with ldPSC[8]. However, studies have shown that among the cohort of patients who progress from small to large-duct involvement, up to half will develop outcomes of death or liver transplantation[8].

**CONCLUSION**

SdPSC is a rare disorder with the potential of progressing to ldPSC. The definitive etiology and pathogenesis of sdPSC and the circumstances that lead to progression to large-duct involvement are not well understood. Strong associations between sdPSC and IBD have been established with suspicion that concurrent sdPSC-IBD may be a key prognostic factor in determining which patients are at risk of progression to ldPSC. Additionally, this association may warrant future studies regarding the need for routine colorectal cancer screening in sdPSC patients with concomitant IBD. Evaluation using the current available literature is limited due to small cohorts and limited data regarding this specific subset of patients. It is therefore crucial for clinicians to continue reporting readily accessible data in hopes that future studies can further characterize which patients are at most risk of progression as large-duct involvement carries a more grim prognosis and requires more diligent surveillance.

**REFERENCES**

1 **Chapman R**, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. *Hepatology* 2010; **51**: 660-678 [PMID: 20101749 DOI: 10.1002/hep.23294]

2 **Karlsen TH**, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. *J Hepatol* 2017; **67**: 1298-1323 [PMID: 28802875 DOI: 10.1016/j.jhep.2017.07.022]

3 **Mertz A**, Nguyen NA, Katsanos KH, Kwok RM. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. *Ann Gastroenterol* 2019; **32**: 124-133 [PMID: 30837784 DOI: 10.20524/aog.2019.0344]

4 **Tabibian JH**, Bowlus CL. Primary sclerosing cholangitis: A review and update. *Liver Res* 2017; **1**: 221-230 [PMID: 29977644 DOI: 10.1016/j.livres.2017.12.002]

5 **Lunder AK**, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, Viktil E, Henriksen M, Hovde Ø, Huppertz-Hauss G, Høie O, Høivik ML, Monstad I, Solberg IC, Jahnsen J, Karlsen TH, Moum B, Vatn M, Negård A. Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. *Gastroenterology* 2016; **151**: 660-669.e4 [PMID: 27342213 DOI: 10.1053/j.gastro.2016.06.021]

6 **Ludwig J**. Small-duct primary sclerosing cholangitis. *Semin Liver Dis* 1991; **11**: 11-17 [PMID: 2047885 DOI: 10.1055/s-2008-1040417]

7 **Björnsson E**, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, Schrumpf E, Chapman RW. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. *Gut* 2002; **51**: 731-735 [PMID: 12377815 DOI: 10.1136/gut.51.5.731]

8 **Björnsson E**, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P. The natural history of small-duct primary sclerosing cholangitis. *Gastroenterology* 2008; **134**: 975-980 [PMID: 18395078 DOI: 10.1053/j.gastro.2008.01.042]

9 **Angulo P**, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. *Hepatology* 2002; **35**: 1494-1500 [PMID: 12029635 DOI: 10.1053/jhep.2002.33202]

10 **Singal AK**, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. *Hepatol Int* 2011; **5**: 808-813 [PMID: 21484124 DOI: 10.1007/s12072-011-9260-4]

11 **Broomé U**, Glaumann H, Lindstöm E, Lööf L, Almer S, Prytz H, Sandberg-Gertzén H, Lindgren S, Fork FT, Järnerot G, Olsson R. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). *J Hepatol* 2002; **36**: 586-589 [PMID: 11983440 DOI: 10.1016/s0168-8278(02)00036-3]

12 **Charatcharoenwitthaya P**, Angulo P, Enders FB, Lindor KD. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. *Hepatology* 2008; **47**: 133-142 [PMID: 17992695 DOI: 10.1002/hep.21960]

13 **Valentino PL**, Wiggins S, Harney S, Raza R, Lee CK, Jonas MM. The Natural History of Primary Sclerosing Cholangitis in Children: A Large Single-Center Longitudinal Cohort Study. *J Pediatr Gastroenterol Nutr* 2016; **63**: 603-609 [PMID: 27504812 DOI: 10.1097/MPG.0000000000001368]

14 **Ringe KI**, Bergquist A, Lenzen H, Kartalis N, Manns MP, Wacker F, Grigoriadis A. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). *Eur J Radiol* 2020; **129**: 109101 [PMID: 32505896 DOI: 10.1016/j.ejrad.2020.109101]

15 **Naess S**, Björnsson E, Anmarkrud JA, Al Mamari S, Juran BD, Lazaridis KN, Chapman R, Bergquist A, Melum E, Marsh SG, Schrumpf E, Lie BA, Boberg KM, Karlsen TH, Hov JR. Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. *Liver Int* 2014; **34**: 1488-1495 [PMID: 24517468 DOI: 10.1111/liv.12492]

16 **Bergquist A**, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, Hultcrantz R, Lööf LA, Sandberg-Gertzén H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. *Clin Gastroenterol Hepatol* 2008; **6**: 939-943 [PMID: 18674735 DOI: 10.1016/j.cgh.2008.03.016]

17 **Fevery J**, Van Steenbergen W, Van Pelt J, Laleman W, Hoffman I, Geboes K, Vermeire S, Nevens F. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD. *Aliment Pharmacol Ther* 2016; **43**: 612-620 [PMID: 26748470 DOI: 10.1111/apt.13516]

18 **Tabibian JH**, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. *Biomed Res Int* 2013; **2013**: 389537 [PMID: 24232746 DOI: 10.1155/2013/389537]

19 **Olsson R**, Björnsson E, Bäckman L, Friman S, Höckerstedt K, Kaijser B, Olausson M. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. *J Hepatol* 1998; **28**: 426-432 [PMID: 9551680 DOI: 10.1016/s0168-8278(98)80316-4]

20 **Yamada S**, Ishii M, Liang LS, Yamamoto T, Toyota T. Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats. *J Gastroenterol* 1994; **29**: 631-636 [PMID: 8000512 DOI: 10.1007/BF02365447]

21 **Hobson CH**, Butt TJ, Ferry DM, Hunter J, Chadwick VS, Broom MF. Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. *Gastroenterology* 1988; **94**: 1006-1013 [PMID: 3345870 DOI: 10.1016/0016-5085(88)90560-4]

22 **Nakazawa T**, Naitoh I, Hayashi K, Sano H, Miyabe K, Shimizu S, Joh T. Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity? *World J Gastroenterol* 2014; **20**: 3245-3254 [PMID: 24696608 DOI: 10.3748/wjg.v20.i12.3245]

23 **Eaton JE**, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. *Gastroenterology* 2013; **145**: 521-536 [PMID: 23827861 DOI: 10.1053/j.gastro.2013.06.052]

24 **Escorsell A**, Parés A, Rodés J, Solís-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. *J Hepatol* 1994; **21**: 787-791 [PMID: 7890895 DOI: 10.1016/s0168-8278(94)80240-8]

25 **Zheng HH**, Jiang XL. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. *Eur J Gastroenterol Hepatol* 2016; **28**: 383-390 [PMID: 26938805 DOI: 10.1097/MEG.0000000000000576]

26 **Rizvi S**, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. *Clin Gastroenterol Hepatol* 2015; **13**: 2152-2165 [PMID: 26051390 DOI: 10.1016/j.cgh.2015.05.035]

27 **Deneau MR**, El-Matary W, Valentino PL, Abdou R, Alqoaer K, Amin M, Amir AZ, Auth M, Bazerbachi F, Broderick A, Chan A, Cotter J, Doan S, El-Youssef M, Ferrari F, Furuya KN, Gottrand M, Gottrand F, Gupta N, Homan M, Kamath BM, Kim KM, Kolho KL, Konidari A, Koot B, Iorio R, Ledder O, Mack C, Martinez M, Miloh T, Mohan P, O'Cathain N, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Jensen MK. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. *Hepatology* 2017; **66**: 518-527 [PMID: 28390159 DOI: 10.1002/hep.29204]

28 **Olsson R**, Glaumann H, Almer S, Broomé U, Lebrun B, Bergquist A, Björnsson E, Prytz H, Danielsson A, Lindgren S. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. *Eur J Intern Med* 2009; **20**: 190-196 [PMID: 19327611 DOI: 10.1016/j.ejim.2008.06.004]

29 **Barakauskienė A**, Speičienė D, Liakina V, Semuchinienė T, Valantinas J. Expression of cytokeratin 7 as a histological marker of cholestasis and stages of primary biliary cirrhosis. *Medicina (Kaunas)* 2011; **47**: 31-38 [PMID: 21681009]

30 **Weismüller TJ**, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. *Gastroenterology* 2017; **152**: 1975-1984.e8 [PMID: 28274849 DOI: 10.1053/j.gastro.2017.02.038]

31 **Wee A**, Ludwig J, Coffey RJ Jr, LaRusso NF, Wiesner RH. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. *Hum Pathol* 1985; **16**: 719-726 [PMID: 4007848 DOI: 10.1016/s0046-8177(85)80158-1]

32 **Miloh T**, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. *Clin Gastroenterol Hepatol* 2009; **7**: 239-245 [PMID: 19121649 DOI: 10.1016/j.cgh.2008.10.019]

33 **Beuers U**, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. *Hepatology* 1992; **16**: 707-714 [PMID: 1505913 DOI: 10.1002/hep.1840160315]

34 **Chazouillères O**, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, Couzigou P, Labayle D, Trinchet JC. Ursodeoxycholic acid for primary sclerosing cholangitis. *J Hepatol* 1990; **11**: 120-123 [PMID: 1975818 DOI: 10.1016/0168-8278(90)90281-u]

35 **Olsson R**, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. *Gastroenterology* 2005; **129**: 1464-1472 [PMID: 16285948 DOI: 10.1053/j.gastro.2005.08.017]

36 **Boberg KM**, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. *Scand J Gastroenterol* 2003; **38**: 991-995 [PMID: 14531538 DOI: 10.1080/00365520310005172]

37 **Cullen SN**, Chapman RW. Review article: current management of primary sclerosing cholangitis. *Aliment Pharmacol Ther* 2005; **21**: 933-948 [PMID: 15813829 DOI: 10.1111/j.1365-2036.2005.02407.x]

38 **Graziadei IW**, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, Rosen CB, Gores GJ, LaRusso NF, Krom RA. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. *Hepatology* 1999; **30**: 1121-1127 [PMID: 10534330 DOI: 10.1002/hep.510300501]

39 **Nikolaidis NL**, Giouleme OI, Tziomalos KA, Patsiaoura K, Kazantzidou E, Voutsas AD, Vassiliadis T, Eugenidis NP. Small-duct primary sclerosing cholangitis. A single-center seven-year experience. *Dig Dis Sci* 2005; **50**: 324-326 [PMID: 15745094 DOI: 10.1007/s10620-005-1604-2]

40 **Liu K**, Wang R, Kariyawasam V, Wells M, Strasser SI, McCaughan G, Corte C, Leong RW. Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. *Liver Int* 2017; **37**: 442-448 [PMID: 27891750 DOI: 10.1111/liv.13328]

41 **Umetsu S**, Notohara K, Nakazawa T, Tsunoda T, Sogo T, Komatsu H, Tanaka A, Tazuma S, Takikawa H, Inui A, Fujisawa T. Long-term outcomes of pediatric-onset primary sclerosing cholangitis: A single-center experience in Japan. *Hepatol Res* 2019; **49**: 1386-1397 [PMID: 31408920 DOI: 10.1111/hepr.13421]

**Footnotes**

**Conflict-of-interest statement:** The authors report no conflicts of interest or financial disclosures relevant to the manuscript nor any funding of financial support received.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 26, 2021

**First decision:** May 3, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Cabezuelo AS **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Gong ZM

**Figure Legends**



**Figure 1 Histologic features in a liver biopsy collected from a patient with normal magnetic resonance cholangiopancreatography and suspected small duct primary sclerosing cholangitis.** A: The H&E shows a portal tract with bile duct senescence (arrow) and mild non-specific, lymphocytic inflammation. B: The Masson’s trichrome stain shows a higher power image of this same portal tract, highlighting the smaller size of the intrahepatic bile ducts when compared to the adjacent hepatic artery (arrowhead).  This stain also shows peribiliary sclerosis that is causing fibrous obliteration of the bile duct epithelium (arrows).  The collagen surrounding the ducts is dense and has a keloid-like appearance. C: A cytokeratin 7 stain was conducted and shows prominent periportal cholangiolar metaplasia of hepatocytes (arrows) with atrophy of the intrahepatic bile ducts (arrowhead).  In patients without chronic biliary obstruction or suboptimal bile flow, cholangiolar metaplasia is not present. D: A copper stain was positive for periportal deposition (arrows), further supporting the presence of chronic biliary obstruction.

**Table 1 Baseline characteristics and outcomes of small duct primary sclerosing cholangitis cohorts**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Study design, population | Study location | Total sdPSC | Females | Age at Dx (yr)1 | F/U (mo)1 | UC | CD | HCC | CCA | AIH | LdPSC conversion | Conversion time (mo)1 | Treatment | | | Liver transplant | Death |
| **UDCA** | **Steroids** | **AZA** |
| Wee *et al*[31], 1984 | Retrospective, Adult | Mayo Clinic | 3 | 1 | 34 | - | 3 | 0 | 0 | 3 | 0 | 0 | - | - | - | - | 0 | 3 |
| Broomé *et al*[11], 2002 | Retrospective, Adult | Sweden | 32 | 12 | 39 | 63 | 13 | 3 | 1 | 0 | 0 | 4 | 115 | 7 | 7 | 6 | 1 | 0 |
| Björnsson *et al*[7], 2002 | Retrospective, Adult | Oslo/Oxford | 33 | 14 | 38 | 106 | 20 | 7 | 0 | 0 | 0 | 4 | - | 7 | - | - | 2 | 2 |
| Angulo *et al*[9], 2002 | Longitudinal cohort, Adult | Mayo Clinic | 18 | 7 | 39 | 126 | 14 | 3 | 0 | 0 | 0 | 3 | 122 | 7 | 0 | 0 | 2 | 1 |
| Nikolaidis *et al*[39], 2005 | Retrospective, Adult | Greece | 6 | - | 32 | 26 | 2 | 1 | 0 | 0 | 0 | 0 | - | 5 | 0 | 5 | 0 | 0 |
| Charatcharoenwitthaya *et al*[12], 2007 | Longitudinal cohort, Adult | Mayo Clinic | 42 | 14 | 35 | 57 | 13 | 3 | 0 | 0 | 0 | 3 | - | 30 | - | 5 | 6 | 1 |
| Miloh *et al*[32],2009 | Retrospective, Pediatric | New York | 16 | 5 | 10 | 78 | 4 | 4 | 0 | 0 | 5 | 0 | - | 16 | - | - | 2 | 0 |
| Olsson *et al*[28],2009 | Retrospective, Adult | Sweden | 7 | 3 | 24 | 71 | 4 | 0 | 0 | 0 | 7 | 0 | - | - | 6 | 6 | 0 | 0 |
| Singal *et al*[10],2011 | Retrospective, Adult | New York/Florida | 25 | 12 | 37 | 39 | 13 | 0 | 0 | 0 | 0 | 0 | - | 15 | 8 | 12 | 1 | 1 |
| Fevery *et al*[17], 2016 | Retrospective, Adult | Belgium | 33 | - | 35 | 144 | 3 | 9 | 0 | 0 | 0 | 0 | - | - | - | - | - | - |
| Valentino *et al*[13], 2016 | Longitudinal cohort, Ped | Boston | 24 | - | 10 | 44 | - | - | - | - | - | 6 | 72 | - | - | - | 2 | 2 |
| Liu *et al*[40],2017 | Retrospective, Adult | Australia | 10 | - | 41 | 96 | - | - | 0 | 0 | - | - | - | - | - | - | - | - |
| Deneau *et al*[27], 2017 | Retrospective, Pediatric | Multi-institutional | 98 | 34 | 10.5 | - | - | - | - | - | 36 | - | - | 75 | - | - | - | - |
| Weismüller *et al*[30], 2017 | Retrospective, Adult | Multi-institutional | 254 | 96 | 37 | - | 67 | 24 | 0 | 0 | - | - | - | - | - | - | - | - |
| Umetsu *et al*[41], 2019 | Retrospective, Pediatric | Japan | 3 | - | 9 | 66 | - | - | 0 | 0 | - | - | - | - | - | - | 0 | 0 |
| Ringe *et al*[14], 2020 | Retrospective, Adult | Germany | 16 | 7 | 29 | 127 | 6 | 4 | - | - | 1 | 5 | 144 | 16 | - | - | - | - |

1Indicates an average.

AIH: Autoimmune hepatitis; AZA: Azathioprine; CCA: Cholangiocarcinoma; CD: Crohn’s Disease; Conversion time (average time from sdPSC diagnosis to ldPSC conversion); F/U: Follow-up (months after initial diagnosis); HCC: Hepatocellular carcinoma; LdPSC: Large duct primary sclerosing cholangitis; SdPSC: Small duct primary sclerosing cholangitis; UC: Ulcerative colitis; UDCA: Ursodeoxycholic acid; -: unknown.